Table 4 Methodological characteristics of included studies by funding type
From: Funding source and the quality of reports of chronic wounds trials: 2004 to 2011
Fully or partly commercially funded | Non-commercially funded | Funding unclear/not reported | |
|---|---|---|---|
(n = 68) | (n = 55) | (n = 44) | |
Number of participants(median (IQ range)) | |||
Overall | 63 (40 to 117) | 52 (28 to 91) | 60 (29 to 98) |
Per treatment arm | 30 (18 to 51) | 26 (14 to 44) | 23 (14 to 41) |
Duration (in months; median (IQ range)) | |||
Overall | 2.8 (1.9 to 5.6) | 3.0 (1.9 to 6.0) | 2.0 (1.2 to 3.5) |
Primary outcome | |||
Complete healing | 17 (25%) | 15 (27%) | 8 (18%) |
Surrogate healing | 26 (38%) | 11 (20%) | 10 (23%) |
Non-healing | 5 (7.4) | 4 (7.3%) | 2 (4.5%) |
None | 20 (29%) | 25 (45%) | 24 (55%) |
Sequence generation | |||
Low RoB | 23 (34%) | 31 (56%) | 14 (32%) |
Unclear RoB | 43 (63%) | 24 (44%) | 30 (68%) |
High RoB | 2 (2.9%) | 0 (0.0)% | 0 (0.0%) |
Allocation concealment | |||
Low RoB | 21 (31%) | 13 (24%) | 7 (16%) |
Unclear RoB | 45 (66%) | 41 (75%) | 37 (84%) |
High RoB | 2 (2.9%) | 1 (1.8%) | 0 (0.0%) |
Blinding of assessors | |||
Low RoB | 23 (34%) | 23 (42%) | 10 (23%) |
Unclear RoB | 19 (28%) | 20 (36%) | 25 (57%) |
High RoB | 26 (38%) | 12 (22%) | 9 (20%) |
Overall RoB | |||
Low RoB | 3 (4.4%) | 5 (9.1%) | 2 (4.5%) |
Unclear RoB | 37 (54%) | 37 (67%) | 33 (75%) |
High RoB | 28 (41%) | 13 (24%) | 9 (20%) |